Lymphomatoid Papulosis is a rare chronic skin condition that presents with clinically benign but histologically malignant characteristics. Despite its histological appearance and similarities to cutaneous lymphoma, the disease typically follows a benign course with relapses and spontaneous regression of the lesions.
It manifests as multiple reddish-brown papules or nodules, mainly appearing on the trunk and limbs. These may present with crusting, a necrotic center, or ulcerations, while others resolve spontaneously, often leaving scars. The course of the disease is characterized by cycles of flare-ups and remissions lasting weeks or months.
Course
Lymphomatoid Papulosis usually has a benign course, with spontaneous resolution of the lesions. However, in some cases, it may progress to Mycosis Fungoides or be associated with Hodgkin’s disease, raising concerns about potential complications.
Etilogy
The exact cause remains unknown, but it is considered a T-cell lymphoproliferative disorder and falls within the spectrum of cutaneous T-cell lymphomas. Some patients may, over the years, develop lymphoproliferative diseases such as folliculotropic mycosis fungoides or primary cutaneous lymphomas. Despite hypotheses linking the condition to viruses such as Human T-lymphotropic virus-1 (HTLV-1) and Epstein-Barr virus (EBV), relevant studies have not confirmed these associations.
Diagnosis
Diagnosis of Lymphomatoid Papulosis is based on histological findings, immunological, cytological, chemical tests, and molecular techniques. These examinations help identify cellular changes and features that differentiate the condition from other dermatologic diseases.
Therapeutic Management
Although the course of Lymphomatoid Papulosis is generally benign, regular monitoring is recommended due to the potential involvement of other organ systems, given its possible association with lymphoma. Treatment is individualized depending on severity:
Watchful waiting in mild forms (due to potential spontaneous regression).
Topical or systemic corticosteroids for rapid remission.
Phototherapy (e.g. narrowband UVB or PUVA) in widespread lesions. In resistant or extensive cases: Methotrexate, retinoids, JAK inhibitors, or biological agents (in selected cases).
